

October 2006

Prescriber Profile Report

USER GUIDE
USER GUIDE



Table of Contents

Introduction 2
Data Sources 2
Prescriber Information 2
Questions. 3
Member Demographics. 3
Cost and Utilization. 3
Your Rank. 4
Legend: Specialty 4
Specialty Benchmarks 4
Top 10 Therapeutic Classes 4
Top 10 Drugs by Cost and Utilization 4
MassHealth Costs for Selected
Prescribed Drugs 5
Excluded Drug List 5

Introduction

The Prescriber Profile Report (PPR) is a practice-management tool that reports your prescribing patterns for fee-for-service MassHealth members. MassHealth members that are excluded from the report are:

- ▶ MassHealth members enrolled in one of the following MassHealth managed care organizations (MCOs):
 - BMC HealthNet Plan;
 - Fallon Community Health Plan;
 - Neighborhood Health Plan; or
 - Network Health; and
- ▶ dual-eligible MassHealth/Medicare members (most of their prescription benefits are the responsibility of Medicare-D plans).

The PPR provides information on selected pharmacy cost and utilization measures that you can use to improve health-care delivery and, ultimately, the health outcomes of your MassHealth members. This user guide explains the information in your PPR.

Prescribers who have written 150 or more prescriptions for MassHealth members in one quarter are included in the report. The PPR is based on paid claims; therefore, the quality of the data is dependent on the accuracy of information submitted on claims. Data is presented for four quarters; the previous three quarters are given for trending purposes. The quarters correspond to calendar-year quarters. Due to the time needed to produce the PPR, there could be a four-to-eight-week lag between the date that the data is extracted and the date reports are mailed. All paid claims for prescription medications have been included, with the exception of some high-cost medications that might otherwise skew the data for most specialties. (Please see the attached Excluded Drug List on page 5.) Claims for the drug Suboxone are also excluded from the study.

Important: This report contains confidential information that must be handled in accordance with state and federal guidelines governing the confidentiality of medical information.

Data Sources

The primary source of data is the MMIS database of paid pharmacy claims, originating from ACS, the company that manages the MassHealth Pharmacy Online Processing System (POPS). The data is supplemented with drug reference information from First DataBank (FDB) and ACS, and address and specialty information from Folio, Inc. (a company that offers information about prescribers), ACS, and MMIS. MassHealth provider status is determined from MMIS provider data.

Prescriber Information

Prescriber information includes the provider's name, address, MassHealth provider number, group number, and group name as it appears in the MassHealth database. Prescribers have been grouped by specialty so that valid comparisons of prescribing patterns can be made. The number of prescribers in your specialty group is also included. Specialty information is critical to support a valid comparison of prescribing patterns among clinicians practicing in the same field of medicine. If you are currently enrolled with a group practice according to the MMIS provider data, the MassHealth group number will also be listed. If you belong to multiple groups, the group number listed will be the group number under which you most recently enrolled. If you cannot be identified in MMIS or do not belong to a group practice, the group number will be blank. If there is a group number listed, the name corresponding to that number will be listed.

The total number of prescriptions dispensed and the number of members for whom drugs are prescribed are compiled using pharmacy claims associated with your DEA number.

If any provider information is incorrect or if there is ever an address change, please update your profile by going to the Folio Web site at www.foliomed.com or calling MassHealth Provider Enrollment and Credentialing at 1-800-841-2900, if you are a MassHealth provider.

Questions

If you have any questions, comments, or observations about the report, or suggestions that may make the report more beneficial, please e-mail Vic Vangel, RPh at vic.vangel@state.ma.us. We appreciate any feedback.

Member Demographics

Demographics displayed in this section of the report are compiled as of the last date the member filled a prescription under your DEA number. These data include information about the MassHealth member's age and gender, and the subpopulations defined below. Demographics are useful in understanding the characteristics of your patient population. MassHealth subpopulations include:

- ▶ **DMH:** Members in this group are enrolled in the Massachusetts Department of Mental Health. In general, these members have serious and persistent mental illness.
- ▶ **Disabled:** Members in this group are enrolled in a MassHealth disabled category. These members may also have Supplemental Security Income (SSI), be enrolled in the Massachusetts Commission for the Blind (MCB), or be HIV positive.
- ▶ **Nursing Facility:** Members residing in long-term-care facilities.

Cost and Utilization

The PPR provides information on selected pharmacy utilization and cost indicators. These indicators were chosen based on their relevance to MassHealth members, feasibility of data collection, and opportunities for improvement. The pharmacy performance indicators are as follows:

- ▶ **Percentage of Brand Rxs Dispensed:** This indicator is the percentage of all prescriptions you prescribed that were for brand medications.
total number of brand prescriptions ÷ total number of prescriptions
- ▶ **Percentage of Controlled Rxs Dispensed:** This indicator is the percentage of all prescriptions you prescribed that were for controlled substances. Controlled substances are medications in DEA classes 2, 3, 4, and 5.
total number of controlled drugs ÷ total number of all prescriptions
- ▶ **Mean Cost per Rx:** This indicator is the average cost of all prescriptions written by you for MassHealth members.
total cost of all prescriptions written ÷ number of prescriptions written
- ▶ **Mean Number of Rxs per Member:** This indicator is the average number of prescriptions you prescribed for MassHealth members.
total number of prescriptions ÷ number of members
- ▶ **Percentage of Members with 5+ Rxs:** This indicator shows the percentage of members for whom you prescribed concomitantly five or more prescriptions for a period of more than 60 continuous days.
total number of members receiving 5 or more prescriptions ÷ total number of members
- ▶ **Percentage of Rxs That Require Prior Authorization (PA):** This indicator measures medications specified by the MassHealth Drug List as requiring PA that were prescribed instead of the preferred drug within the therapeutic class.
total number of prescriptions requiring PA ÷ total number of prescriptions

Your Rank

Your rank on each of the measures is expressed in quartiles and identified using stars in the following way:

- **** Top quartile (indicates highest level of performance)
- *** Second quartile
- ** Third quartile
- * Fourth quartile

The quartile rate ranges are provided for each measure.

Legend: Specialty

This table shows where most prescribers within your specialty are ranked by showing the percentage of prescribers who fall into each quartile of that indicator.

Specialty Benchmarks

Benchmarks represent the 90th percentile provider rate for prescribing. These benchmarks were calculated by using only prescribers within your specialty.



Top 10 Therapeutic Classes

Your Therapeutic Classes

This table shows your ranking by cost of therapeutic classes. All strengths and dosage forms of drugs within therapy classes are included. The percentage column represents the percent of total prescription costs attributable to the therapeutic class.

Specialty Therapeutic Classes

This table shows the specialty ranking by cost of therapeutic classes for comparison purposes.

Graphs

Each indicator is shown on a graph comparing your rate with both your specialty's average rankings and the established benchmark.

Top 10 Drugs by Cost and Utilization

Your Top 10 Drugs by Cost

This shows your ranking of drugs by cost, using actual prescription cost (all strengths and dosage forms of that product are included in the grouping). The percentage column represents the percent of total prescription costs attributable to the drug.

Specialty Top 10 Drugs by Cost

This shows the specialty ranking of the top 10 drugs by cost for comparison purposes.

Your Top 10 Drugs by Utilization

This shows your ranking of drugs by using your total count of prescriptions dispensed, within the specified time frame, for that drug. Each drug includes all strengths and dosage forms of that product. The percent column represents the percentage of total prescriptions for this drug.

Specialty Top 10 Drugs by Utilization

This shows the specialty ranking of drugs by total count of prescriptions dispensed, for comparison purposes.

MassHealth Costs for Selected Prescribed Drugs

This page shows the price that MassHealth pays for some of the more commonly prescribed drugs within your specialty. The price shown is the average price paid for the drug for the most commonly seen prescribed quantity for the time period shown. Rank is based on total counts of prescriptions within your specialty for the time period.

The PA key on this page represents:

- Y Drugs requires PA (Prior Authorization) as specified by MHDL (MassHealth Drug List)
- B Brand name drug that requires PA due to the fact that an A-rated generic is available as specified by MHDL
- A Drug requires PA for specific ages as specified by MHDL
- Q Drug requires PA for specific quantities as specified by MHDL

Excluded Drug List

The drugs listed below have been excluded from the report because of their high cost, which could skew the results of the report.

Therapeutic Code (HIC3)	Therapeutic Class Description	Example Drug Name	Specialty Exceptions (Included in reports for:)
A1C	Inotropic drugs	milrinone	
B1B	Pulmonary antihypertension, endothelin	Tracleer	
B1C	Pulmonary antihypertension, prostaglandin	Flolan	
B1D	Pulmonary antihypertension, T5 inhibitor	Revatio	
B3A	Mucolytics	Pulmozyme	
C5B	Protein replacements	Freamine IV solution	
C5O	Solutions, miscellaneous	Flolan diluent	
C8A	Metallic poisons, agents to treat	Exjade, Desferal	
D6A	Drugs to treat chronic inflammation	Remicade	
D7D	Drugs to treat hereditary tyrosinemia	Orfadin	
H0E	Agents to treat multiple sclerosis	Copaxone	Neurology
H6I	Drugs to treat amyotrophic lateral sclerosis	Rilutek	
L1A	Antipsoriatic agents, systemic	Amevive, Raptiva, Soriatane	Dermatology
M0E	Antihemophilic factors	Kogenate	

Therapeutic Code (HIC3)	Therapeutic Class Description	Example Drug Name	Specialty Exceptions (Included in reports for:)
M0F	Factor IX preparations	factor IX complex	
M9K	Heparin and related preparations	Arixtra, Fragmin, Lovenox	
M9T	Thrombin inhibitors, selective	argatroban	
N1B	Hematinics, other	Epogen	
N1C	Leukocyte (WBC) stimulants	Neupogen	
N1D	Platelet-reducing agents	Agrylin	
N1E	Platelet-proliferation stimulants	Neumega	
P1A	Growth hormones	Humatrope	
P1B	Somatostatic agents	Sandostatin	
P1M	LHRH (GNRH) agonist analogs	Synarel	
P1P	LHRH (GNRH) agonist pituitary suppressants-central precocious puberty	leuprolide	
P1Q	Growth hormone receptor antagonists	Somavert	
P4D	Hyperparathyroid treatments: vitamin D analog	Hectorol	
P4M	Calcimimetic, parathyroid calcium enhancer	Sensipar	
P7A	Insulin-like growth factor-1 hormones	Increlex	
S2H	Anti-inflammatory/antiarthritic	Synvisc	
S2J	Anti-inflammatory/tumor necrosis	Enbrel, Humira	Rheumatology
S2M	Anti-inflammatory/interleukin-1 receptors	Kineret	
S7A	Neuromuscular blocking agents	Botox	
V1A	Alkylating agents	Cytosan	Hematology/Oncology
V1B	Antimetabolics	methotrexate, Xeloda	Hematology/Oncology Rheumatology
V1C	Vinca alkaloids	vincristine	Hematology/Oncology
V1D	Antibiotic antineoplastics	doxorubicin	Hematology/Oncology

Therapeutic Code (HIC3)	Therapeutic Class Description	Example Drug Name	Specialty Exceptions (Included in reports for:)
V1E	Steroid antineoplastics	Megace	
V1F	Antineoplastics, miscellaneous	Taxol, Vepesid	Hematology/Oncology
V1I	Antidote agents	leucovorin	Hematology/Oncology
V1J	Antiandrogenic agents	Casodex	Hematology/Oncology
V1K	Antineoplastics antibody/antibody drug complexes	Herceptin	Hematology/Oncology
V1N	Selective retinoid X receptor agonists	Targretin gel	Hematology/Oncology
V1O	Antineoplastic LHRH (GNRH) agonists	leuprolide	Hematology/Oncology
V1Q	Antineoplastic systemic enzyme	Gleevec	Hematology/Oncology
V1W	Antineoplastic, EGF receptor blocker recomb MC antibody	Herceptin	Hematology/Oncology
V1X	Antineoplastic, HUM VEGF inhibitor recomb MC antibody	Avastin	Hematology/Oncology
W1M	Streptogramins	Synercid	Infectious disease
W1O	Oxazolidinones	Zyvox	Infectious disease
W4K	Antiprotozoal drugs, miscellaneous	atovaquone	Infectious disease
W5B	Antivirals, HIV-specific, other	Retrovir, Videx	Infectious disease
W5C	Antivirals, HIV-specific protease inhibitor	Invirase	Infectious disease
W5D	Antiviral monoclonal antibodies	Synagis	Infectious disease
W5F	Hepatitis B treatment agents	Baraclude, Hepsera	Infectious disease
W5G	Hepatitis C treatment	Rebetol	Infectious disease
W5I	Antivirals, HIV-specific, nucleotide analog, RTI	Viread	Infectious disease
W5J	Antivirals, HIV-specific, nucleoside analog, RTI	Zerit	Infectious disease
W5K	Antivirals, HIV-specific, nonnucleoside, RTI	Sustiva, Viramune	Infectious disease
W5L	Antivirals, HIV-specific, nucleoside analog, RTI combination	Combivir, Trizivir	Infectious disease
W5M	Antivirals, HIV-specific protease-inhibitor combination	Kaletra	Infectious disease
W5N	Antivirals, HIV-specific, fusion inhibitors	Fuzeon	Infectious disease

Therapeutic Code (HIC3)	Therapeutic Class Description	Example Drug Name	Specialty Exceptions (Included in reports for:)
W5O	Antivirals, HIV-specific, nucleoside-nucleotide analog	Truvada	Infectious disease
W5P	Antivirals, HIV-specific nonpeptidic protease inhibitor	Aptivus	Infectious disease
W5Q	Antivirals, HIV-specific combination	Atripla	Infectious disease
W5U	Antivirals, HIV-specific HIV-1 Integrase strand transfer inhibitor	Isentress	Infectious disease
W7K	Hepatitis B	Hepatitis B immune globulin	Infectious disease
W9D	Glycylcyclines	Tygacil	
Z1D	Enzyme replacements (ubiquitous)	imiglucerase	
Z1I	Metabolic disease enzyme replacement	Cerezyme	
Z2E	Immunosuppressives	Sandimmune	
Z2G	Immunomodulators	Intron A	
Z2L	Monoclonal antibodies to immunoglobulin E (IGE)	Xolair	
Z2M	Immunosupp-monoclonal AB inhibiting	Zenapax	



Quality Improvement Activities

Prescribers who have been identified as outliers may receive:

- ▶ a letter identifying potential opportunities for improvement;
- ▶ a phone call to conduct a prescribers' practice review, which may identify appropriate reasons for the outlier status; or
- ▶ a visit from a MassHealth staff pharmacist to discuss prescribing habits.

**We hope this report provides valuable information
for your practice.**